Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 19;10(7):1149. doi: 10.3390/vaccines10071149

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

The immunogenicity of inactivated Omicron vaccine. (A) Mice model of Omicron immunogenicity. Mice were intramuscularly injected with a middle dose of the vaccine at day 0 (D0) and the NAb Tilter was tested at D14 of the vaccine against Omicron (n = 10/group). (B) Mice model of Omicron immunogenicity with middle (6 μg/dose) and high (12 μg/dose) dose twice on D0/D21, respectively. (C) The NAb Tilter of the vaccine against Omicron at D14 by the microtitration method. (D) The GMT level of the neutralizing antibody in each group. (E) The NAb Tilter against Omicron with middle (6 μg/dose) and high (12 μg/dose) doses of inactivated Omicron vaccine was performed at D28, D35, and D42 by the microtitration method (n = 10/group). Each circle represents the data of a mouse.